SEC Company Response from NRX Pharmaceuticals, (NRXP) — Jun 16, 2022
NRX Pharmaceuticals, Inc.
Date: June 16, 2022 · CIK: 0001719406 · Accession: 0001104659-22-071869
AI Filing Summary & Sentiment
File numbers found in text: 333-265492
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Attention: Mr. Daniel Crawford NRX Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-265492)
Dear Mr. Crawford:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 (the “S-3”) of NRx Pharmaceuticals, Inc. (the “Company”) be accelerated to June 21, 2022 at 4:00 p.m. E.S.T. or as soon thereafter as may be practicable.
We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the S-3. If you have any questions regarding the foregoing, please contact David Huntington of Paul Weiss Rifkin Wharton & Garrison LLP at (212) 373-3124 or dhuntington@paulweiss.com.
Very truly yours,
By:
/s/ Alessandra Daigneault
Show Raw Text
CORRESP
1
filename1.htm
NRx Pharmaceuticals, Inc.
1201 N. Market Street
Suite 111
Wilmington, Delaware
19801
June 16, 2022
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Daniel Crawford
NRX Pharmaceuticals, Inc.
Registration Statement on
Form S-3 (File No. 333-265492)
Dear Mr. Crawford:
Pursuant to Rule 461 of the Securities Act of 1933, as amended,
we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 (the “S-3”)
of NRx Pharmaceuticals, Inc. (the “Company”) be accelerated to June 21, 2022 at 4:00 p.m. E.S.T.
or as soon thereafter as may be practicable.
We understand that the Staff will consider this request as confirmation
by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities
covered by the S-3. If you have any questions regarding the foregoing, please contact David Huntington of Paul Weiss Rifkin Wharton &
Garrison LLP at (212) 373-3124 or dhuntington@paulweiss.com.
Very truly yours,
By:
/s/ Alessandra Daigneault
Name:
Alessandra Daigneault
Title:
Chief Corporate Officer, General Counsel and Corporate Secretary